BTK inhibitor 4b   Click here for help

GtoPdb Ligand ID: 10094

Synonyms: compound 4b [PMID: 30216722]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This compound is reported as a selective inhbitor of Bruton's tyrosine kinase (BTK) [2]. Compared to existing BTK inhibitors it has a novel aminotriazine scaffold. Inhibitor 4b has been advanced to preclinical studies for evaluation of its anti-inflammatory potential. This is one of the chemical structures claimed in Carna Bioscience's patent WO2015012149A1 [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 136.25
Molecular weight 498.19
XLogP 4.19
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCc1c(cccc1n1ccc2c(c1=O)c(F)cc(c2)C1CC1)c1nc(N)nc(n1)Nc1cnn(c1)C
Isomeric SMILES OCc1c(cccc1n1ccc2c(c1=O)c(F)cc(c2)C1CC1)c1nc(N)nc(n1)Nc1cnn(c1)C
InChI InChI=1S/C26H23FN8O2/c1-34-12-17(11-29-34)30-26-32-23(31-25(28)33-26)18-3-2-4-21(19(18)13-36)35-8-7-15-9-16(14-5-6-14)10-20(27)22(15)24(35)37/h2-4,7-12,14,36H,5-6,13H2,1H3,(H3,28,30,31,32,33)
InChI Key RQYDQAPLARKISN-UHFFFAOYSA-N
Immunopharmacology Comments
Inhibitor 4b is a selective BTK inhibitor that is being evaluated for preclinical anti-inflammatory efficacy [2]. Based on in vivo tests in rodents it is being considered as a lead compound for the treatment of rheumatoid arthritis. BTK activity is implicated in a number of pathologies that are driven by B-cell or macrophage activation, such as B-cell malignancies, asthma, rheumatoid arthritis, and systemic lupus erythematosus. BTK inhibitors have already proven useful in the clinic (see ibrutinib and acalabrutinib).